Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, provides an update on the latest data from the Phase II PRIMO study (NCT03372057) of duvelisib (DUV), an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory peripheral T cell lymphoma (R/R PTCL). Data obtained from the mature dose optimization phase demonstrate that there was a lower rate of early disease progression in the patient group receiving DUV at 75mg BID (n=13) compared to the 25mg BID group (n=20). Initial results of the ongoing dose-expansion phase, in which 25 patients received DUV at 75 mg BID followed by 25 mg BID, indicate an overall response rate (ORR) of 40-50% and reasonable single-agent activity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.